Sos1 inhibitor and use thereof

A compound of Formula I below, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof:

• wherein
• is a single bond or a double bond;
• Z1 is N or CH;
• when Z1 is N, then Z2 and Z3 are both CHR1 and is a single bond, or Z2 and Z3 are both CR1 and is a double bond;
• when Z1 is CH, then Z2 is N or CR1, Z3 is CR1, and is a double bond;
• or
• when Z1 is N, Z2 and Z3 are both CR1, and is a double bond, then two R1 may be optionally linked to each other together with the carbon atom to which they are attached to form a thiophene or pyrrole ring;
• each R1 is independently selected from the group consisting of H, halogen, CN, OH, NRbRc, C1-C6 alkoxy, C1-C6 acylamino, C1-C6 alkylsulfonylamino, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C10 aryl, C6-C10 aryloxy, (C6-C10 aryl)-(C1-C6 alkyl)oxy and C6-C10 arylamino;
• R′ and R″ are each independently H or C1-C3 alkyl, or R′ and R″ may be taken together with the carbon atom to which they are attached to form C3-C4 cycloalkyl, and said C1-C3 alkyl and C3-C4 cycloalkyl may be optionally substituted with at least one halogen, OH, CN, C1-C3 alkoxy or NRbRc;
• A is Cy1 or Cy1-Y-Cy2;
• Y is O, S, or a direct bond;
• Cy1 is C6-C10 aryl or 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms selected from N, O and S;
• Cy1 may be optionally substituted with 1 to 3 R2a;
• R2a is selected from the group consisting of H, halogen, OH, CN, oxo, SF5, NRbRc, —Si(C1-3 alkyl)3, —SO2Rb, —C(O)Rb, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkyl and
• R21 is H, halogen, OH, NRbRc, C1-C6 alkoxy or C1-C6 acyloxy, and R22 and R23 are each independently H, halogen or C1-C2 alkyl;
• Cy2 is C6-C10 aryl, phenyl fused with C3-C6 cycloalkyl, or 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms selected from N, O and S;
• Cy2 may be optionally substituted with 1 to 3 R2b;
• R2b is selected from the group consisting of H, halogen, OH, CN, oxo, NRbRc;
• C1-C6 alkyl;
• C1-C6 alkyl substituted with halogen, CN, OH, NRbRc or C1-C6 alkoxy;
• C1-C6 alkyl optionally interrupted by 1 to 3 oxygen atoms and/or nitrogen atoms;
• and C1-C6 alkyl substituted with hydroxy-(C1-C6 alkyl)amino-;
• B is H, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy-C1-C6 alkyl, C1-C6 alkyl substituted with NRbRc, —(CH2)o-Cy3 or —(CH2)o-Cy3-W-Cy4;
• W is NH, C(O) or a direct bond;
• o is an integer of 0 or 1;
• Cy3 is selected from the group consisting of C3-C8 cycloalkyl, C3-C8 cycloalkenyl, 5- or 6-membered saturated or partially unsaturated heterocycloalkyl containing 1 or 2 heteroatoms selected from N, O and S, bridged bicyclic C5-10 cycloalkyl, C6-C10 aryl, phenyl fused with a 5- or 6-membered cyclic group containing 1 heteroatom selected from N, O and S, and 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O and S;
• Cy3 may be optionally substituted with 1 to 3 R3a,
• R3a is selected from the group consisting of H, halogen, OH, CN, oxo, C1-C6 alkyl;
• C1-C6 alkyl substituted with halogen, OH, CN or C1-C6 alkoxy;
• C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 haloalkylamino, C1-C6 hydroxyalkylamino, (C3-C6 cycloalkyl)carbonylamino, —NRbRc, —NRbCORc—NRbC(O)ORc—SO2Rb, —C(O)Rb, —C(O)ORb, —NRbSO2Rc and —CONRb1Rc1;
• Cy4 is selected from the group consisting of saturated or partially unsaturated 4- to 10-membered heterocycloalkyl containing 1 or 2 heteroatoms selected from N, O or S, C6-C10 aryl, and 5- or 6-membered heteroaryl containing 1 to 4 heteroatoms selected from N, O and S;
• Cy4 may be optionally substituted with 1 to 3 R3b,
• R3b is H, deuterium, halogen, OH, CN, oxo, NRbRc, C1-C6 alkyl, C1-C6 alkyl substituted with deuterium, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy-C1-C6 alkyl, C1-C6 alkoxy or C1-C6 haloalkoxy;
• Rb and Rc are each independently H or C1-C6 alkyl;
• and
• one of Rb1 and Rc1 is H or C1-C6 alkyl, and the other of Rb1 and Rc1 is H, C1-C6 alkyl, C1-C6 alkyl substituted with NRbRc, or C1-C6 alkyl substituted with C1-C6 alkoxy.